Real-world data continued to support immunotherapy expansion in HER2-low metastatic breast cancer, with a cohort showing trastuzumab deruxtecan delivering a median progression-free survival of 9.1 months. The analysis also identified biomarkers linked to outcomes, suggesting tumor biology markers may be useful for refining patient selection beyond trial eligibility. In parallel, the broader dataset of oncology studies and translational tools reflects how imaging, AI, and outcome-linked biomarkers are increasingly used to complement clinical decision-making in routine settings. For developers, this underlines the value of collecting real-world evidence tied to measurable biological predictors. Taken together, these findings support continued adoption of targeted and immune-adjacent modalities while reinforcing the push toward biomarker-informed positioning.